Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
01. August 2024 09:00 ET
|
Outpace Bio
Seattle, WA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- – Financing syndicate led by RA Capital Management with significant support from a world-class group of existing and new healthcare investors –...
AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
09. August 2023 09:00 ET
|
Renovaro Biosciences Inc.
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary...
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
08. Juni 2023 08:45 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application...
Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
18. Mai 2023 08:00 ET
|
Outpace Bio
Seattle, WA, May 18, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced it will...
Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
09. Mai 2023 09:00 ET
|
Outpace Bio
Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an...
Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform
17. Oktober 2022 08:30 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Today, Enochian BioSciences (the Company) announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could...
Flerie Invest AB leads $52m acquisition of Swedish Biopharma Facility from Charles River
15. Oktober 2021 01:00 ET
|
FLERIE INVEST AB
STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Flerie Invest, a biotech and pharma investment firm with offices in Stockholm and London, led a syndicate of investors in the $52m acquisition of...
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure
14. Juni 2021 07:00 ET
|
Enochian Biosciences, Inc.
LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that...
Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy
24. März 2021 18:00 ET
|
Enochian Biosciences, Inc.
LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in...
Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference
22. Februar 2021 17:15 ET
|
Enochian Biosciences, Inc.
LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will...